UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~March~~May 2522, 2013

Tamir Biotechnology, Inc.

(Exact name of registrant as specified in its charter)

~~000~~0-11088

(Commission File Number)

Delaware		22-2369085
(State or other jurisdiction of incorporation)		(I.R.S. Employer Identification No.)

~~12750~~5825 ~~High Bluff~~Oberlin Drive, ~~Suite 190,~~ San Diego, CA ~~92130~~92121

(Address of principal executive offices, with zip code)

(732) 823-1003

(Registrant's telephone number, including area code)

11 Deer Park Drive, Suite 204, Princeton Corporate Plaza, Monmouth Junction, NJ 08852

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 47.01 ~~Changes~~Regulation inFD ~~Registrant’s Certifying Accountant~~Disclosure.

~~(a)~~ On ~~March~~May 2522, 2013, ~~following~~an Administrative Law Judge issued an Initial Decision revoking the ~~recommendation~~registration of ~~its~~the ~~Audit~~common ~~Committee,~~stock of Tamir Biotechnology, Inc. (the “Company”), ~~dismissed CohnReznick~~under ~~LLP~~Section 12(~~f/k/a~~j) ~~J.H.~~of ~~Cohn~~the ~~LLP~~Securities Exchange Act of 1934, as amended (the “Exchange Act”) because the Company had previously been delinquent in filing periodic reports with the Securities and Exchange Commission (the “~~CohnReznick~~Commission”). asThe Initial Decision will become final upon entry by the Commission of an order of finality, which is expected to occur approximately 21 days following the issuance of the Initial Order. Upon entry of the order of finality by the Commission, broker-dealers will be prohibited from executing trades in the Company’s ~~independent~~ ~~registered~~common stock, and as a result, public trading ~~accounting~~of ~~firm.~~the Company’s common stock will cease.

The Company ~~audit~~is ~~report of~~currently ~~CohnReznick~~considering onits ~~the~~options ~~financial~~and ~~statements~~may ofseek ~~the~~to ~~Company~~re-register asits ofcommon ~~July~~stock ~~31,~~under ~~2010~~Section ~~and~~12 ~~2009~~of ~~and~~the ~~for~~Exchange Act after the ~~years~~Initial ~~then~~Decision ~~ended,~~becomes ~~which~~final ~~are~~ by filing a Form 10 with the ~~most~~Commission. ~~recent~~However, ~~fiscal~~there ~~years~~is ~~for~~no ~~which~~assurance that the Company will ~~has~~resume ~~audited~~being ~~financial~~a ~~statements~~publicly traded company under the Exchange Act. Accordingly, ~~did~~once ~~not~~the ~~contain~~Initial ~~any~~Order ~~adverse~~becomes ~~opinion~~final, orand ~~disclaimer~~until ofsuch ~~opinion~~time, ~~nor~~if ~~was~~ever, ~~such~~as ~~report~~the ~~qualified~~Company oreffects ~~modified~~such asre-registration, tothe ~~uncertainty,~~disclosure ~~audit~~requirements ~~scope~~under orthe ~~accounting~~Exchange ~~principles~~Act, ~~except that such~~including ~~report~~the ~~included~~filing anof ~~explanatory~~periodic ~~paragraph~~reports ~~relating~~and toproxy ~~our~~statements, ~~ability~~will tonot ~~continue~~be asapplicable ato ~~going~~the ~~concern~~Company.

~~During~~In May 2013, the ~~years ended~~Company ~~July~~concluded ~~31,~~a ~~2010~~confirmatory ~~and~~study ~~2009,~~regarding ~~and~~the ~~through~~purity ~~the~~and ~~date~~enzymatic activity of ~~their~~ONCONASE® ~~dismissal,~~(ranpirnase). The ~~there~~study ~~were~~confirmed nothat ~~disagreements~~as ~~between~~shown in the ~~Company~~proof-of-concept ~~and~~skin ~~CohnReznick as~~penetration tostudies ~~any~~performed ~~matter~~by ofthe ~~accounting~~Company ~~principles~~in ~~or practices~~2012, ~~financial~~ONCONASE® is ~~statement~~indeed ~~disclosure,~~capable orof ~~auditing~~being ~~scope~~delivered ortransdermally ~~procedure,~~and ~~which~~that ~~disagreements, if~~ONCONASE® ~~not~~remained ~~resolved~~active tofollowing ~~the~~such ~~satisfaction~~delivery throughout the length of ~~CohnReznick,~~the ~~would~~evaluation ~~have~~across ~~caused~~the ~~CohnReznick~~full torange ~~make~~of ~~reference~~ranpirnase inconcentrations ~~their~~tested. ~~reports~~The onCompany believes that the ~~financial~~purity and activity ~~statements~~profiles ~~for~~of ~~such~~ONCONASE® ~~years~~appear to ~~the~~be ~~subject~~acceptable ~~matter~~to ofpermit ~~the~~further ~~disagreement~~non-clinical studies.

~~CohnReznick~~As previously reported, ~~has~~the ~~been~~Company ~~provided~~is ~~with~~a party to a ~~copy~~Memorandum of ~~the~~Understanding ~~disclosure~~(“MOU”), ~~under~~with ~~this~~US ~~Item~~Pharmacia 4International, Inc.01 (a)together with Unilab and ~~has~~its ~~been~~affiliates, ~~requested~~“USPI”), under which USPI is to ~~furnish~~be agranted ~~letter~~exclusive ~~stating~~marketing, ~~whether~~sales, and distribution orrights ~~not~~for itONCONASE® for ~~agrees~~the ~~with~~treatment of Human Papillioma Virus (HPV) in Europe in consideration of $1 million (the ~~foregoing~~“License ~~statements.~~Fee”) ~~Such~~to ~~letter~~be ispaid ~~attached~~by USPI to the Company as milestones are achieved. An initial payment of $405,000 towards the License Fee was made by USPI to the Company in December, 2011, and an ~~Exhibit~~additional payment in the amount of $95,000 was made to ~~this~~the ~~Form~~Company 8in 2012 following the results of the 2012 proof-Kof-concept study. USPI and the Company have agreed that the results of the confirmatory study described above entitle the Company to an additional $100,000 milestone payment, which amount was paid by USPI to the Company in June 2013, bringing the total payments made to the Company under the MOU to $600,000.

(b) On March 25, 2013, following the recommendation of its Audit Committee, the Company engaged Goldman Kurland and Mohidin, LLP (“GKM”), as its independent accountants to audit the Company's financial statements for its fiscal years ended July 31, 2011, 2012 and 2013. In the Company's two most recent fiscal years and subsequent interim periods prior to such engagement, the Company has not (itself or through someone acting on its behalf) consulted with GKM on either (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements, or (ii) any matter that was either the subject of a disagreement, as that term is defined in Item 304(a)(1)(iv) of Regulation S-~~K and the related instructions to Item 304 of Regulation S~~2-~~K, or a reportable event, as that term is defined in Item 304(a)(1)(v) of Regulation S-K.~~

~~Item 9.01 Financial Statements and Exhibits~~SIGNATURES

~~Exhibit 16.1 Letter~~Pursuant to the requirements of ~~CohnReznick~~the ~~LLP,~~Securities Exchange ~~dated~~Act ~~March~~of 251934, ~~2013~~ the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

~~SIGNATURES~~ TAMIR BIOTECHNOLOGY, INC.

~~Pursuant~~Date: toJune ~~the requirements of the Securities Exchange Act of 1934~~11, ~~the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~2013

	TAMIR BIOTECHNOLOGY, INC.
Date: March 28, 2013	By:	/s/ Joanne M. Barsa
	Name:	Joanne M. Barsa
	Title:	Chief Financial Officer

By: /s/ Joanne Barsa

Name: Joanne Barsa

Title: Chief Financial Officer and Secretary

Filing Compare · TAMIR BIOTECHNOLOGY, INC.